Systemic bile acid sensing by G protein-coupled bile acid receptor 1 (GPBAR1) promotes PYY and GLP-1 release

British Journal of Pharmacology

Volumn 169, Issue 3, 2013, Pages 671-684

  Ullmer, C ^a   Alvarez Sanchez, R ^a   Sprecher, U ^a   Raab, S ^a   Mattei, P ^a   Dehmlow, H ^a   Sewing, S ^a   Iglesias, A ^a   Beauchamp, J ^a   Conde Knape, K ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

bile acid; cyclic adenosine monophosphate; GLP 1 secretion; glucagon like peptide 1; glucose tolerance; incretin

Indexed keywords

1 [4 [3 (HYDROXYIMINO) 3 (2 METHYLPYRIDIN 4 YL) 1 ORTHO TOLYLPROPYL]PHENYL]PIPERIDINE 4 CARBOXYLIC ACID; 2 [1 [4 [3 (HYDROXYIMINO) 3 (2 METHYLPYRIDIN 4 YL) 1 ORTHO TOLYLPROPYL]PHENYL]PIPERIDINE 4 CARBOXAMIDO]ETHANESULFONIC ACID; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BILE ACID; DEOXYCHOLIC ACID; G PROTEIN COUPLED BILE ACID RECEPTOR 1; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LITHOCHOLIC ACID; PEPTIDE YY; RO 5527239; SITAGLIPTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR SECRETION; CONTROLLED STUDY; DRUG ACTIVATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG IDENTIFICATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; GENE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GPBAR1 GENE; HAPLORHINI; HORMONE RELEASE; IN VITRO STUDY; IN VIVO STUDY; L CELL; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ORAL GLUCOSE TOLERANCE TEST; PHARMACOLOGICAL STIMULATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOASSAY; TREATMENT OUTCOME;

ANIMALS; CELL LINE; CHO CELLS; CRICETULUS; DIABETES MELLITUS, TYPE 2; ENTEROENDOCRINE CELLS; GASTROINTESTINAL AGENTS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; ISONIPECOTIC ACIDS; MACACA FASCICULARIS; MALE; METABOLIC DETOXICATION, PHASE II; MICE; MICE, MUTANT STRAINS; MICE, TRANSGENIC; OXIMES; PEPTIDE YY; PIPERIDINES; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT PROTEINS; TAURINE;

EID: 84877804442     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12158     Document Type: Article

References (51)

1. Adrian TE, Ballantyne GH, Longo WE, Bilchik AJ, Graham S, Basson MD, et al. (1993). Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon. Gut 34: 1219-1224.
2. Adrian TE, Gariballa S, Parekh KA, Thomas SA, Saadi H, Al Kaabi J, et al. (2012). Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia 55: 2343-2347.
3. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
4. Angelin B, Bjorkhem I, Einarsson K, Ewerth S, (1982). Hepatic uptake of bile acids in man. Fasting and postprandial concentrations of individual bile acids in portal venous and systemic blood serum. J Clin Invest 70: 724-731.
5. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, et al. (2002). Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418: 650-654.
6. Bock G, Dalla Man C, Micheletto F, Basu R, Giesler PD, Laugen J, et al. (2010). The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol (Oxf) 73: 189-196.
7. Cao W, Tian W, Hong J, Li D, Tavares R, Noble L, et al. (2013). Expression of bile acid receptor TGR5 in gastric adenocarcinoma. Am J Physiol Gastrointest Liver Physiol 304: G322-G327.
8. Chen L, McNulty J, Anderson D, Liu Y, Nystrom C, Bullard S, et al. (2010). Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats. J Pharmacol Exp Ther 334: 164-170.
9. Cipriani S, Mencarelli A, Bruno A, Renga B, Distrutti E, Santucci L, et al. (2013). GPBAR1 activation protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs and ASA in mice. Br J Pharmacol 168: 225-237.
10. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ, (2002). Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 172: 355-362.
11. Drucker DJ, (2001). Minireview: the glucagon-like peptides. Endocrinology 142: 521-527.
12. Drucker DJ, Nauck MA, (2006). The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705.
13. Duan H, Ning M, Chen X, Zou Q, Zhang L, Feng Y, et al. (2012). Design, Synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists. J Med Chem 55: 10475-10489.
14. Field BC, Wren AM, Peters V, Baynes KC, Martin NM, Patterson M, et al. (2010). PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans. Diabetes 59: 1635-1639.
15. Fu-Cheng X, Anini Y, Chariot J, Castex N, Galmiche JP, Roze C, (1997). Mechanisms of peptide YY release induced by an intraduodenal meal in rats: neural regulation by proximal gut. Pflugers Arch 433: 571-579.
16. Furness JB, Jones C, Nurgali K, Clerc N, (2004). Intrinsic primary afferent neurons and nerve circuits within the intestine. Prog Neurobiol 72: 143-164.
17. Garg SK, Ritchie PJ, Moser EG, Snell-Bergeon JK, Freson BJ, Hazenfield RM, (2011). Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized double-blind trial. Diabetes Obes Metab 13: 137-143.
18. Glicksman C, Pournaras DJ, Wright M, Roberts R, Mahon D, Welbourn R, et al. (2010). Postprandial plasma bile acid responses in normal weight and obese subjects. Ann Clin Biochem 47 (Pt 5): 482-484.
19. Harach T, Pols TW, Nomura M, Maida A, Watanabe M, Auwerx J, et al. (2012). TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep 2: 430. doi: 10.1038/srep00430
20. Katsuma S, Hirasawa A, Tsujimoto G, (2005). Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 329: 386-390.
21. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, et al. (2003). A G protein-coupled receptor responsive to bile acids. J Biol Chem 278: 9435-9440.
22. Keitel V, Reinehr R, Gatsios P, Rupprecht C, Gorg B, Selbach O, et al. (2007). The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology 45: 695-704.
23. Keitel V, Donner M, Winandy S, Kubitz R, Haussinger D, (2008). Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun 372: 78-84.
24. Keitel V, Cupisti K, Ullmer C, Knoefel WT, Kubitz R, Haussinger D, (2009). The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 50: 861-870.
25. Keitel V, Ullmer C, Haussinger D, (2010). The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biol Chem 391: 785-789.
26. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
27. Kosinski JR, Hubert J, Carrington PE, Chicchi GG, Mu J, Miller C, et al. (2012). The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin. Obesity (Silver Spring) 20: 1566-1571.
28. Lavoie B, Balemba OB, Godfrey C, Watson CA, Vassileva G, Corvera CU, et al. (2010). Hydrophobic bile salts inhibit gallbladder smooth muscle function via stimulation of GPBAR1 receptors and activation of KATP channels. J Physiol 588 (Pt 17): 3295-3305.
29. Li T, Holmstrom SR, Kir S, Umetani M, Schmidt DR, Kliewer SA, et al. (2011). The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol Endocrinol 25: 1066-1071.
30. Lubbers T, Bohringer M, Gobbi L, Hennig M, Hunziker D, Kuhn B, et al. (2007). 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 17: 2966-2970.
31. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
32. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, et al. (2002). Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 298: 714-719.
33. Parker HE, Wallis K, le Roux CW, Wong KY, Reimann F, Gribble FM, (2012). Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br J Pharmacol 165: 414-423.
34. Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, et al. (2009). Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 17: 1671-1677.
35. Perides G, Laukkarinen JM, Vassileva G, Steer ML, (2010). Biliary acute pancreatitis in mice is mediated by the G-protein-coupled cell surface bile acid receptor Gpbar1. Gastroenterology 138: 715-725.
36. Plaisancie P, Dumoulin V, Chayvialle JA, Cuber JC, (1996). Luminal peptide YY-releasing factors in the isolated vascularly perfused rat colon. J Endocrinol 151: 421-429.
37. Pols TW, Nomura M, Harach T, Lo Sasso G, Oosterveer MH, Thomas C, et al. (2011). TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 14: 747-757.
38. Poole DP, Godfrey C, Cattaruzza F, Cottrell GS, Kirkland JG, Pelayo JC, et al. (2010). Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol Motil 22: 814-825, e227-e818.
39. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM, (2008). Glucose sensing in L cells: a primary cell study. Cell Metab 8: 532-539.
40. Roberts RE, Glicksman C, Alaghband-Zadeh J, Sherwood RA, Akuji N, le Roux CW, (2011). The relationship between postprandial bile acid concentration, GLP-1, PYY and ghrelin. Clin Endocrinol (Oxf) 74: 67-72.
41. Rocca AS, Brubaker PL, (1999). Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140: 1687-1694.
42. Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, et al. (2008). Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci U S A 105: 16767-16772.
43. Shaham O, Wei R, Wang TJ, Ricciardi C, Lewis GD, Vasan RS, et al. (2008). Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. Mol Syst Biol 4: 214.
44. Shang Q, Saumoy M, Holst JJ, Salen G, Xu G, (2010). Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am J Physiol Gastrointest Liver Physiol 298: G419-G424.
45. Steinert RE, Beglinger C, (2011). Nutrient sensing in the gut: interactions between chemosensory cells, visceral afferents and the secretion of satiation peptides. Physiol Behav 105: 62-70.
46. Suzuki T, Oba K, Igari Y, Matsumura N, Watanabe K, Futami-Suda S, et al. (2007). Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch 74: 338-343.
47. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, et al. (2009). TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10: 167-177.
48. Wallis K, Walters JR, Gabe S, (2009). Short bowel syndrome: the role of GLP-2 on improving outcome. Curr Opin Clin Nutr Metab Care 12: 526-532.
49. Wang YD, Chen WD, Yu D, Forman BM, Huang W, (2011). The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice. Hepatology 54: 1421-1432.
50. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, et al. (2006). Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439: 484-489.
51. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, et al. (2006). Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 30: 1729-1736.